BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33468319)

  • 1. Impact of intra-operative factors upon peri-operative outcomes in women undergoing hyperthermic intraperitoneal chemotherapy for gynecologic cancer.
    Chichura A; Chambers LM; Costales AB; Yao M; Gruner M; Morton M; Rose PG; Vargas R; Michener CM; Debernardo R
    Gynecol Oncol; 2021 Apr; 161(1):194-201. PubMed ID: 33468319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
    Morton M; Chambers LM; Costales AB; Chichura A; Gruner M; Horowitz MP; Rose PG; Yao M; Debernardo R; Michener C
    Gynecol Oncol; 2021 Jan; 160(1):45-50. PubMed ID: 33067001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified frailty index predicts postoperative complications in women with gynecologic cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Chambers LM; Chalif J; Yao M; Chichura A; Morton M; Gruner M; Costales AB; Horowitz M; Chau DB; Vargas R; Rose PG; Michener CM; Debernardo R
    Gynecol Oncol; 2021 Aug; 162(2):368-374. PubMed ID: 34083027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A guide to establishing a hyperthermic intraperitoneal chemotherapy program in gynecologic oncology.
    Chambers LM; Costales AB; Crean-Tate K; Kuznicki M; Morton M; Horowitz M; Jagielo T; Rose PG; Michener C; Vargas R; Debernardo R
    Gynecol Oncol; 2020 Sep; 158(3):794-802. PubMed ID: 32624234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer.
    Costales AB; Chambers L; Chichura A; Rose PG; Mahdi H; Michener CM; Yao M; Debernardo R
    J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101844. PubMed ID: 32590110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer.
    Gruner M; Chambers LM; Yao M; Chichura A; Morton M; Costales AB; Horowitz M; Rose PG; Debernardo R; Michener CM
    Gynecol Oncol; 2021 Sep; 162(3):645-651. PubMed ID: 34247768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative bevacizumab does not increase complications following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    King BH; Baumgartner JM; Kelly KJ; Marmor RA; Lowy AM; Veerapong J
    PLoS One; 2020; 15(12):e0243252. PubMed ID: 33270763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Chambers LM; Yao M; Morton M; Gruner M; Chichura A; Horowitz M; Costales AB; Rose PG; Michener CM; Debernardo R
    Gynecol Oncol; 2021 May; 161(2):389-395. PubMed ID: 33551202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for perforated low-grade appendiceal mucinous neoplasms.
    Abudeeb H; Selvasekar CR; O'Dwyer ST; Chakrabarty B; Malcolmson L; Renehan AG; Wilson MS; Aziz O
    Surg Endosc; 2020 Dec; 34(12):5516-5521. PubMed ID: 31993814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and predictive value of blood lactate levels during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): a comparative analysis.
    Tonello M; Barina A; Turchet F; De Simoni O; Alfieri R; Franzato B; Gruppo M; Dengo B; Deffenu D; Di Pasquale D; Fiore T; Pietropaoli C; Munaron S; Zanardo G; Sommariva A; Pilati P
    Updates Surg; 2021 Feb; 73(1):313-319. PubMed ID: 33146888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Doxorubicin for 90 Minutes
    Acs M; Halmy L; Isgandarova S; Blaj S; Gerken M; Hormann B; Piso P
    Anticancer Res; 2022 Feb; 42(2):1019-1029. PubMed ID: 35093903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in elderly women with epithelial ovarian cancer: analysis of a prospective registry.
    Chambers LM; Yao M; Morton M; Chichura A; Costales AB; Horowitz M; Gruner MF; Rose PG; Michener CM; DeBernardo R
    Int J Gynecol Cancer; 2021 Jul; 31(7):1021-1030. PubMed ID: 34006567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of incisional hernia in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: an observational clinical study from a tertiary oncology referral care center in India.
    Ray M; Kumar A; Maranna H
    World J Surg Oncol; 2024 May; 22(1):132. PubMed ID: 38760663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of ultrasound-guided bilateral rectus sheath block in patients undergoing cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy - a retrospective study.
    Wang S; Liu P; Gao T; Guan L; Li T
    BMC Anesthesiol; 2020 Aug; 20(1):197. PubMed ID: 32781985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.
    Somashekhar SP; Yethadka R; Kumar C R; Ashwin KR; Zaveri S; Rauthan A
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):577-581. PubMed ID: 31677939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience with the use of HIPEC in advanced serous ovarian cancer after complete and optimal cytoreduction.
    Tsip NP; Kopetskiy VI; Polentsov YO; Yegorov MY; Vakulenko GO; Svintsitskiy VS
    Exp Oncol; 2021 Mar; 43(1):67-72. PubMed ID: 33785709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
    Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
    Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute kidney injury in ovarian cancer patients undergoing cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy.
    Sin EI; Chia CS; Tan GHC; Soo KC; Teo MC
    Int J Hyperthermia; 2017 Sep; 33(6):690-695. PubMed ID: 28540777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy.
    Zhou S; Jiang Y; Liang J; Pei W; Zhou Z
    World J Surg Oncol; 2021 May; 19(1):151. PubMed ID: 34001125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Base Excess as a Predictor of Complications in Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
    Eng OS; Dumitra S; O'Leary M; Wakabayashi M; Dellinger TH; Han ES; Lee SJ; Benjamin Paz I; Singh G; Lee B
    Ann Surg Oncol; 2017 Sep; 24(9):2707-2711. PubMed ID: 28560593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.